Skip to content

Esophageal complications from atrial fibrillation ablation

Esophageal complications from atrial fibrillation ablation - Esophageal complications from atrial fibrillation ablation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000050346
Enrollment
150
Registered
2023-10-01
Start date
2023-04-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation/ tachycardia, Esophageal complication

Interventions

Sponsors

Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients undergoing ablation for atrial fibrillation/tachycardia 2. patients who are 20 years of age or older at the time of consent 3. patients who have given their free written consent to participate in this study

Exclusion criteria

Exclusion criteria: 1. patients deemed by the investigator to be inappropriate for participation in the study 2. patients with contraindications to upper gastrointestinal endoscopy (e.g. patients with allergies to pharyngeal anesthetics that preclude their use) 3. patients with a history of upper gastrointestinal disease prior to ablation 4. patients who have difficulty understanding the study in the investigator's judgment

Design outcomes

Primary

MeasureTime frame
esophageal complication (erythema/erosion, ulcer, perforation)

Secondary

MeasureTime frame
time course of complication recurrence rate of AF or AT rate of the complication other than esophagus

Countries

Japan

Contacts

Public ContactAtsushi Murakami

Kobe University Graduate School of Medicine Division of Cardiovascular Medicine, Department of Internal Medicine

mura0649@med.kobe-u.ac.jp+81783825846

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026